Why BIAF was halted on Oct 8 2026: japan patent grant
BIAF+15.1%on Thu Oct 8 2026
bioAffinity Technologies, Inc. Common Stock was up 15.1% on the day at $7.09, ranked #1 on 150× its usual five-minute volume, when TapeRank recorded this trading halt at 12:08 ET during regular hours when it was halted. TapeRank recorded 2 events for BIAF that day, between 08:09 and 12:08 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 08:09 ETMOVER · PRE-MARKET
$7.40 · ▲ 20.1% ON THE DAY · 216× 5M RVOL · RANK #3
STRETCHEDCONFIDENCE4/5BIAF is up 12.1% pre-market, with an 11.24% surge in the last five minutes. The catalyst is an intended Japanese patent grant for its CyPath lung cancer test, but the announcement provides no quantified commercial impact, making the move larger than the disclosed news supports.
WHYA 12% move on an intended patent grant with no disclosed financial terms is large relative to the catalyst.ANALYZED 08:06 ET · 3 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 08:09 ET
LAST7.40DAY▲ 20.1%5 MIN▲ 12.46%5M RVOL216×5M $VOL$3.4MFLOAT*592KRANK#3SESSIONPRE-MARKETVWAP7.05HOD7.65LOD6.03OR HIGH—OR LOW—PREV CLOSE6.16PM HIGH7.65PM LOW6.03GAP▲ 18.51% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 12:08 ETHALT · REGULAR
HALTED AT $7.09 · ▲ 15.1% ON THE DAY · 150× 5M RVOL · RANK #1
STRETCHEDCONFIDENCE5/5BIAF is up 15.1% to $7.09 after news that Japan intends to grant a patent for its CyPath Lung test, while the company also announced an approximately $4 million registered direct offering at $6.122 per share. The patent milestone is concrete but unquantified, making a double-digit move stretched, and the offering creates direct dilution risk into the move.
WHYA 15.1% gain on an intended patent grant with no disclosed financial impact is large relative to the news, especially alongside shares being offered near $6.122.ANALYZED 12:12 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 12:08 ET
LAST7.09DAY▲ 15.1%5 MIN▼ 9.68%5M RVOL150×5M $VOL$1.9MFLOAT*592KRANK#1SESSIONREGULARVWAP7.97HOD9.38LOD6.03OR HIGH6.80OR LOW6.31PREV CLOSE6.16PM HIGH8.33PM LOW6.03GAP▲ 3.08%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
THE SESSION
- 09:30 ETOpened at $6.35, +3.1% on the previous close of $6.16
- 10:08 ETRegular-session high, $9.38
- 12:07 ETHalted (LUDP); resumed 12:17 ET, after 10 minutes
- 15:25 ETRegular-session low, $5.50
- 15:59 ETLast trade of the regular session, $5.65, -8.3% on the previous close of $6.16
- Volume: 30.3M shares in regular hours, 4.8M before the open
BIAF opened at $6.35 and rose to a session high of $9.38 by 10:08 ET after news that Japan’s patent office intended to grant a patent for the company’s CyPath Lung cancer test. TapeRank tied the early move to that patent news but noted that it provided no quantified commercial impact; it later also flagged an approximately $4 million registered direct offering at $6.122 per share as dilution risk. After a 10-minute halt beginning at 12:07 ET, the stock reversed, reaching a $5.50 low at 15:25 ET before ending at $5.65, below the previous close.
WRITTEN THU OCT 15 2026 18:03 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list